Wuhan Easy Diagnosis Biomedicine Co.,Ltd. - Laporan Laba Rugi (TTM)

Wuhan Easy Diagnosis Biomedicine Co.,Ltd.
CN ˙ SZSE
CN¥ 19.03 ↓ -0.06 (-0.31%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Wuhan Easy Diagnosis Biomedicine Co.,Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2022
01-01
2022
03-31
2022
06-30
2022
09-30
2023
01-01
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
Revenue 682 959 1,608 1,740 2,257 2,830 4,640 6,942 8,361 10,530 8,415 5,815 3,686 750 438 366 349 350 359
Change (%) 40.72 67.61 8.23 29.74 25.37 63.97 49.60 20.45 25.94 -20.08 -30.91 -36.60 -79.67 -41.55 -16.40 -4.65 0.24 2.57
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 134 210 360 421 555 707 1,198 2,055 2,541 3,992 3,551 2,656 2,018 310 138 97 95 218 240
Change (%) 57.02 71.28 16.97 31.97 27.43 69.42 71.50 23.64 57.08 -11.04 -25.21 -24.03 -84.65 -55.47 -29.55 -2.48 129.81 10.15
% of Revenue 19.62 21.89 22.37 24.18 24.59 25.00 25.83 29.61 30.39 37.91 42.20 45.68 54.74 41.32 31.48 26.53 27.13 62.20 66.80
Gross Operating Profit 548 749 1,248 1,319 1,702 2,122 3,442 4,886 5,820 6,538 4,864 3,159 1,668 440 300 269 254 132 119
Change (%) 36.74 66.58 5.72 29.02 24.69 62.15 41.98 19.11 12.34 -25.60 -35.06 -47.18 -73.64 -31.75 -10.36 -5.43 -48.01 -9.90
% of Revenue 80.38 78.11 77.63 75.82 75.41 75.00 74.17 70.39 69.61 62.09 57.80 54.32 45.26 58.68 68.52 73.47 72.87 37.80 33.20
SG&A 93 129 174 207 233 294 345 400 441 955 919 824 754 304 283 302 286 168 136
Change (%) 38.16 34.38 19.27 12.65 26.13 17.32 16.03 10.25 116.40 -3.74 -10.38 -8.50 -59.66 -7.09 6.72 -5.18 -41.15 -19.11
% of Revenue 13.71 13.46 10.79 11.89 10.33 10.39 7.43 5.77 5.28 9.07 10.92 14.17 20.45 40.57 64.49 82.33 81.87 48.06 37.90
R&D 47 70 86 100 114 133 139 140 209 388 393 403 340 141 135 125 121 110 107
Change (%) 49.72 23.25 15.80 13.89 16.78 4.77 0.97 49.08 85.52 1.13 2.71 -15.79 -58.37 -4.24 -7.91 -2.95 -9.48 -2.40
% of Revenue 6.85 7.29 5.36 5.74 5.04 4.69 3.00 2.02 2.50 3.69 4.67 6.94 9.21 18.87 30.91 34.05 34.66 31.29 29.78
OpEx 263 415 628 738 926 1,147 1,704 2,629 3,231 5,395 4,907 3,907 3,122 757 504 479 461 496 541
Change (%) 57.86 51.51 17.48 25.56 23.80 48.55 54.27 22.93 66.96 -9.05 -20.38 -20.10 -75.76 -33.38 -4.94 -3.79 7.69 9.08
% of Revenue 38.53 43.22 39.07 42.41 41.04 40.53 36.72 37.87 38.65 51.23 58.31 67.19 84.69 100.95 115.05 130.82 131.99 141.80 150.80
Operating Income 419 545 979 1,002 1,331 1,683 2,936 4,313 5,130 5,135 3,508 1,908 564 -7 -66 -113 -112 -146 -182
Change (%) 29.98 79.86 2.31 32.81 26.45 74.48 46.90 18.94 0.10 -31.68 -45.62 -70.41 -101.26 827.59 71.16 -1.03 30.96 24.66
% of Revenue 61.47 56.78 60.93 57.59 58.96 59.47 63.28 62.13 61.35 48.77 41.69 32.81 15.31 -0.95 -15.05 -30.82 -31.99 -41.80 -50.80
Interest Expense -1 -1 -1 -1 -1 -2 -2 -2 -2 -3 -3 -5 -3 -10 -11 -8 -10 -1 -1
Change (%) -55.95 113.20 6.91 -49.46 180.54 -13.95 13.86 17.89 40.11 -13.96 69.30 -46.14 290.99 5.41 -24.84 24.57 -87.60 -41.92
% of Revenue -0.22 -0.07 -0.09 -0.09 -0.03 -0.07 -0.04 -0.03 -0.03 -0.03 -0.03 -0.09 -0.07 -1.40 -2.53 -2.27 -2.97 -0.37 -0.21
Net Income 353 469 808 848 1,118 1,413 2,461 3,594 4,246 4,208 2,895 1,561 515 75 32 28 11 75 39
Change (%) 32.85 72.36 4.96 31.81 26.39 74.14 46.04 18.14 -0.89 -31.21 -46.09 -66.98 -85.46 -57.92 -12.72 -61.61 605.38 -47.93
% of Revenue 51.79 48.89 50.28 48.76 49.54 49.94 53.04 51.77 50.78 39.97 34.40 26.84 13.98 10.00 7.20 7.51 3.03 21.29 10.81

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista